{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:23:01Z","timestamp":1789845781501,"version":"4.0.1"},"reference-count":151,"publisher":"Bentham Science Publishers Ltd.","issue":"27","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>Chronic prostatitis is a highly prevalent condition that significantly impacts\nthe quality of life and fertility of men. Because of its heterogeneous nature, there is no\ndefinitive treatment, which requires ongoing research into its etiology. Additionally, the\nassociation between prostatitis and an elevated risk of prostate cancer highlights the importance\nof comprehending androgen involvement in prostatitis. This paper examines\nthe current understanding of androgen signaling in prostatitis and explores contemporary\ntherapeutic approaches. It was reviewed Medline articles comprehensively, using\nkeywords such as nonbacterial prostatitis, prostatitis infertility, androgen role in prostatitis,\nand chronic pelvic pain. Several cellular targets are linked to androgen signaling.\nNotably, the major tyrosine phosphatase activity (cPAcP) in normal human prostate is influenced\nby androgen signaling, and its serum levels inversely correlate with prostate\ncancer progression. Androgens also regulate membrane-associated zinc and pyruvate\ntransporters transduction in prostate cells, suggesting promising avenues for novel drug\ndevelopment aimed at inhibiting these molecules to reduce cancer tumor growth. Various\ntherapies for prostatitis have been evaluated, including antibiotics, anti-inflammatory\nmedications (including bioflavonoids), neuromodulators, alpha-blockers, 5\u03b1-reductase\ninhibitors, and androgen receptor antagonists. These therapies have demonstrated\nvarying degrees of success in ameliorating symptoms.In conclusion, aging decreases circulating\nT and intraprostatic DHT, altering the proper functioning of the prostate, reducing\nthe ability of androgens to maintain normal Zn2+ levels, and diminishing the secretion\nof citrate, PAcP, and other proteins into the prostatic fluid. The Zn2+-transporter decreases\nor is absent in prostate cancer, so the pyruvate transporter activates. Consequently,\nthe cell ATP increases, inducing tumor growth.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0109298673279207231228070533","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T00:04:32Z","timestamp":1705795472000},"page":"4249-4266","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Current Understanding of Androgen Signaling in Prostatitis and its\nTreatment: A Review"],"prefix":"10.2174","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5096-8840","authenticated-orcid":true,"given":"Marisa","family":"Cabeza","sequence":"first","affiliation":[{"name":"Departamento de Sistemas Biol\u00f3gicos, Universidad Aut\u00f3noma Metropolitana-Xochimilco, Calzada del\nHueso #1100, CDMX 04960, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"293","volume":"1","author":"Huggins C.","year":"1941","unstructured":"Huggins C.; Hodges C.V.; Studies on prostatic cancer. Cancer Res  1941,1(4),293-297","journal-title":"Cancer Res"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S0090-4295(00)01073-6","volume":"57","author":"Han M.","year":"2001","unstructured":"Han M.; Piantadosi S.; Zahurak M.L.; Sokoll L.J.; Chan D.W.; Epstein J.I.; Walsh P.C.; Partin A.W.; Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. Urology  2001,57(4),707-711","journal-title":"Urology"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1677\/erc.1.00950","volume":"12","author":"Veeramani S.","year":"2005","unstructured":"Veeramani S.; Yuan T.C.; Chen S.J.; Lin F.F.; Petersen J.E.; Shaheduzzaman S.; Srivastava S.; MacDonald R.G.; Lin M.F.; Cellular prostatic acid phosphatase: A protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. Endocr Relat Cancer  2005,12(4),805-822","journal-title":"Endocr Relat Cancer"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0303-7207(95)03544-H","volume":"111","author":"Garcia-Arenas R.","year":"1995","unstructured":"Garcia-Arenas R.; Lin F-F.; Lin D.; Jin L-P.; Shih C.C.; Chang C.; Lin M.F.; The expression of prostatic acid phosphatase is transcriptionally regulated in human prostate carcinoma cells. Mol Cell Endocrinol  1995,111(1),29-37","journal-title":"Mol Cell Endocrinol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.febslet.2004.06.083","volume":"571","author":"Tanaka M.","year":"2004","unstructured":"Tanaka M.; Kishi Y.; Takanezawa Y.; Kakehi Y.; Aoki J.; Arai H.; Prostatic acid phosphatase degrades lysophosphatidic acid in seminal plasma. FEBS Lett  2004,571(1-3),197-204","journal-title":"FEBS Lett"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/S0022-5347(17)36285-7","volume":"149","author":"Sakai H.","year":"1993","unstructured":"Sakai H.; Yogi Y.; Minami Y.; Yushita Y.; Kanetake H.; Saito Y.; Prostate specific antigen and prostatic acid phosphatase immunoreactivity as prognostic indicators of advanced prostatic carcinoma. J Urol  1993,149(5 Part 1),1020-1023","journal-title":"J Urol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.21149\/spm.v58i2.7797","volume":"58","author":"Castillejos-Molina R.A.","year":"2016","unstructured":"Castillejos-Molina R.A.; Gabilondo-Navarro F.B.; Prostate cancer. Salud Publica Mex  2016,58(2),279-284","journal-title":"Salud Publica Mex"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0022-5347(17)44057-2","volume":"137","author":"Ahmann F.R.","year":"1987","unstructured":"Ahmann F.R.; Schifman R.B.; Prospective comparison between serum monoclonal prostate specific antigen and acid phosphatase measurements in metastatic prostatic cancer. J Urol  1987,137(3),431-434","journal-title":"J Urol"},{"key":"ref=9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14081970","volume":"14","author":"Vu P.L.","year":"2022","unstructured":"Vu P.L.; Vadakekolathu J.; Idri S.; Nicholls H.; Cavaignac M.; Reeder S.; Khan M.A.; Christensen D.; Pockley A.G.; McArdle S.E.; A Mutated Prostatic Acid Phosphatase (PAP) peptide-based vaccine induces pap-specific CD8 t cells with ex vivo cytotoxic capacities in HHDII\/DR1 Transgenic Mice. Cancers  2022,14(8)","journal-title":"Cancers"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"Ferlay J.","year":"2015","unstructured":"Ferlay J.; Soerjomataram I.; Dikshit R.; Eser S.; Mathers C.; Rebelo M.; Parkin D.M.; Forman D.; Bray F.; Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer  2015,136(5),E359-E386","journal-title":"Int J Cancer"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1530\/jrf.0.0750035","volume":"75","author":"Kavanagh J.P.","year":"1985","unstructured":"Kavanagh J.P.; Sodium, potassium, calcium, magnesium, zinc, citrate and chloride content of human prostatic and seminal fluid. Reproduction  1985,75(1),35-41","journal-title":"Reproduction"},{"key":"ref=12","first-page":"61","volume":"16","author":"Gilany K.","year":"2015","unstructured":"Gilany K.; Minai-Tehrani A.; Savadi-Shiraz E.; Rezadoost H.; Lakpour N.; Exploring the human seminal plasma proteome: An unexplored gold mine of biomarker for male infertility and male reproduction disorder. J Reprod Infertil  2015,16(2),61-71","journal-title":"J Reprod Infertil"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1084\/jem.76.6.527","volume":"76","author":"Huggins C.","year":"1942","unstructured":"Huggins C.; Neal W.; Coagulation and liquefaction of semen. J Exp Med  1942,76(6),527-541","journal-title":"J Exp Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1530\/jrf.0.0680051","volume":"68","author":"Kavanagh J.P.","year":"1983","unstructured":"Kavanagh J.P.; Darby C.; Creatine kinase and ATPase in human seminal fluid and prostatic fluid. Reproduction  1983,68(1),51-56","journal-title":"Reproduction"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/S0022-5347(05)65725-4","volume":"166","author":"Lin M.F.","year":"2001","unstructured":"Lin M.F.; Lee M.S.; Zhou X.W.; Andressen J.C.; Meng T.C.; Johansson S.L.; West W.W.; Taylor R.J.; Anderson J.R.; Lin F.F.; Decreased expression of cellular prostatic acid phosphatase increases tumorigenicity of human prostate cancer cells. J Urol  2001,166(5),1943-1950","journal-title":"J Urol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1006\/scbi.1998.0086","volume":"9","author":"Stenman U.H.","year":"1999","unstructured":"Stenman U.H.; Leinonen J.; Zhang W.M.; Finne P.; Prostate-specific antigen. Semin Cancer Biol  1999,9(2),83-93","journal-title":"Semin Cancer Biol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"16249","DOI":"10.1016\/S0021-9258(18)71614-1","volume":"264","author":"Andersson S.","year":"1989","unstructured":"Andersson S.; Bishop R.W.; Russell D.W.; Expression cloning and regulation of steroid 5 \u03b1-reductase, an enzyme essential for male sexual differentiation. J Biol Chem  1989,264(27),16249-16255","journal-title":"J Biol Chem"},{"key":"ref=18","first-page":"1","volume":"7","author":"Franklin R. B.","year":"2008","unstructured":"Franklin R. B.; Zou J.; Yu Z.; Costello L. C.; EAAC1 is expressed in rat and human prostate epithelial cells; functions as a high-affinity L-aspartate transporter; and is regulated by prolactin and testosterone. BMC Biochem  2008,7,1-8","journal-title":"BMC Biochem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.bbrc.2008.07.056","volume":"374","author":"Takayama K.","year":"2008","unstructured":"Takayama K.; Horie-Inoue K.; Ikeda K.; Urano T.; Murakami K.; Hayashizaki Y.; Ouchi Y.; Inoue S.; FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells. Biochem Biophys Res Commun  2008,374(2),388-393","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/onc.2010.436","volume":"30","author":"Takayama K.","year":"2011","unstructured":"Takayama K.; Tsutsumi S.; Katayama S.; Okayama T.; Horie-Inoue K.; Ikeda K.; Urano T.; Kawazu C.; Hasegawa A.; Ikeo K.; Gojyobori T.; Ouchi Y.; Hayashizaki Y.; Aburatani H.; Inoue S.; Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells. Oncogene  2011,30(5),619-630","journal-title":"Oncogene"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.1038\/sj.onc.1205663","volume":"21","author":"Gnanapragasam V.J.","year":"2002","unstructured":"Gnanapragasam V.J.; Robson C.N.; Neal D.E.; Leung H.Y.; Regulation of FGF8 expression by the androgen receptor in human prostate cancer. Oncogene  2002,21(33),5069-5080","journal-title":"Oncogene"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"e2024357119","DOI":"10.1073\/pnas.2024357119","volume":"119","author":"van Heijster F.H.A.","year":"2022","unstructured":"van Heijster F.H.A.; Breukels V.; Jansen K.C.F.J.; Schalken J.A.; Heerschap A.; Carbon sources and pathways for citrate secreted by human prostate cancer cells determined by NMR tracing and metabolic modeling. Proc Natl Acad Sci  2022,119(14),e2024357119","journal-title":"Proc Natl Acad Sci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"17499","DOI":"10.1074\/jbc.274.25.17499","volume":"274","author":"Costello L.C.","year":"1999","unstructured":"Costello L.C.; Liu Y.; Zou J.; Franklin R.B.; Evidence for a zinc uptake transporter in human prostate cancer cells which is regulated by prolactin and testosterone. J Biol Chem  1999,274(25),17499-17504","journal-title":"J Biol Chem"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/pros.23767","volume":"79","author":"Li C.","year":"2019","unstructured":"Li C.; He C.; Xu Y.; Xu H.; Tang Y.; Chavan H.; Duan S.; Artigues A.; Forrest M.L.; Krishnamurthy P.; Han S.; Holzbeierlein J.M.; Li B.; Alternol eliminates excessive ATP production by disturbing Krebs cycle in prostate cancer. Prostate  2019,79(6),628-639","journal-title":"Prostate"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0162-0134(99)00225-1","volume":"78","author":"Costello L.C.","year":"2000","unstructured":"Costello L.C.; Franklin R.B.; Liu Y.; Kennedy M.C.; Zinc causes a shift toward citrate at equilibrium of the m-aconitase reaction of prostate mitochondria. J Inorg Biochem  2000,78(2),161-165","journal-title":"J Inorg Biochem"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nrurol.2016.89","volume":"13","author":"Verze P.","year":"2016","unstructured":"Verze P.; Cai T.; Lorenzetti S.; The role of the prostate in male fertility, health and disease. Nat Rev Urol  2016,13(7),379-386","journal-title":"Nat Rev Urol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0304-3835(03)00441-5","volume":"200","author":"Hasumi M.","year":"2003","unstructured":"Hasumi M.; Suzuki K.; Matsui H.; Koike H.; Ito K.; Yamanaka H.; Regulation of metallothionein and zinc transporter expression in human prostate cancer cells and tissues. Cancer Lett  2003,200(2),187-195","journal-title":"Cancer Lett"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"e4604","DOI":"10.1371\/journal.pone.0004604","volume":"4","author":"Sukhorukov V.M.","year":"2009","unstructured":"Sukhorukov V.M.; Bereiter-Hahn J.; Anomalous diffusion induced by cristae geometry in the inner mitochondrial membrane. PLoS One  2009,4(2),e4604","journal-title":"PLoS One"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s42255-018-0002-y","volume":"1","author":"Bader D.A.","year":"2018","unstructured":"Bader D.A.; Hartig S.M.; Putluri V.; Foley C.; Hamilton M.P.; Smith E.A.; Saha P.K.; Panigrahi A.; Walker C.; Zong L.; Martini-Stoica H.; Chen R.; Rajapakshe K.; Coarfa C.; Sreekumar A.; Mitsiades N.; Bankson J.A.; Ittmann M.M.; O\u2019Malley B.W.; Putluri N.; McGuire S.E.; Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer. Nat Metab  2018,1(1),70-85","journal-title":"Nat Metab"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3390\/membranes12100916","volume":"12","author":"Li L.","year":"2022","unstructured":"Li L.; Wen M.; Run C.; Wu B.; OuYang B.; Experimental investigations on the structure of yeast mitochondrial pyruvate carriers. Membranes  2022,12(10),916","journal-title":"Membranes"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3390\/biology9110407","volume":"9","author":"Ques\u00f1ay J.E.N.","year":"2020","unstructured":"Ques\u00f1ay J.E.N.; Pollock N.L.; Nagampalli R.S.K.; Lee S.C.; Balakrishnan V.; Dias S.M.G.; Moraes I.; Dafforn T.R.; Ambrosio A.L.B.; Insights on the quest for the structure-function relationship of the mitochondrial pyruvate carrier. Biology  2020,9(11),407","journal-title":"Biology"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/0090-4295(79)90421-7","volume":"13","author":"Caldamone A.A.","year":"1979","unstructured":"Caldamone A.A.; Freytag M.K.; Cockett A.T.K.; Cockett T.K.; Seminal zinc and male infertility. Urology  1979,13(3),280-281","journal-title":"Urology"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/BF01952862","volume":"50","author":"Bedwal R.S.","year":"1994","unstructured":"Bedwal R.S.; Bahuguna A.; Zinc, copper and selenium in reproduction. Experientia  1994,50(7),626-640","journal-title":"Experientia"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/19396368.2010.516306","volume":"57","author":"Bj\u00f6rndahl L.","year":"2011","unstructured":"Bj\u00f6rndahl L.; Kvist U.; A model for the importance of zinc in the dynamics of human sperm chromatin stabilization after ejaculation in relation to sperm DNA vulnerability. Syst Biol Reprod Med  2011,57(1-2),86-92","journal-title":"Syst Biol Reprod Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1016\/j.fertnstert.2010.07.1050","volume":"94","author":"Barratt C.L.","year":"2010","unstructured":"Barratt C.L.; De Jonge C.J.; Clinical relevance of sperm DNA assessment: An update. Fertility and Sterility  2010,94(6),1958-1953","journal-title":"Fertility and Sterility"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0090-4295(76)90305-8","volume":"7","author":"Fair W.R.","year":"1976","unstructured":"Fair W.R.; Couch J.; Wehner N.; Prostatic antibacterial factor identity and significance. Urology  1976,7(2),169-177","journal-title":"Urology"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/jn\/118.5.622","volume":"118","author":"Reeves P.G.","year":"1988","unstructured":"Reeves P.G.; O\u2019Dell B.L.; Zinc deficiency in rats and angiotensin-converting enzyme activity: Comparative effects on lung and testis. J Nutr  1988,118(5),622-626","journal-title":"J Nutr"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/pros.2990240307","volume":"24","author":"Kavanagh J. P.","year":"1994","unstructured":"Kavanagh J. P.; Isocitric and citric acid in human prostatic and seminal fluid: Implications for prostatic metabolism and secretion. Prostate  1994,24(3),139-142","journal-title":"Prostate"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1476-4598-5-14","volume":"5","author":"Singh K.K.","year":"2006","unstructured":"Singh K.K.; Desouki M.M.; Franklin R.B.; Costello L.C.; Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues. Mol Cancer  2006,5(1),14","journal-title":"Mol Cancer"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0090-4295(97)00235-5","volume":"49","author":"Roberts R.O.","year":"1997","unstructured":"Roberts R.O.; Lieber M.M.; Bostwick D.G.; Jacobsen S.J.; A review of clinical and pathological prostatitis syndromes. Urology  1997,49(6),809-821","journal-title":"Urology"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/0090-4295(93)90584-W","volume":"41","author":"De La Rosette J.J.M.C.H.","year":"1993","unstructured":"De La Rosette J.J.M.C.H.; Hubregtse M.R.; Meuleman E.J.H.; Stolk-engelaar M.V.M.; Debruyne F.M.J.; Diagnosis and treatment of 409 patients with prostatitis syndromes. Urology  1993,41(4),301-307","journal-title":"Urology"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S0022-5347(01)66357-2","volume":"155","author":"Persson B.E.","year":"1996","unstructured":"Persson B.E.; Ronquist G.; Evidence for a mechanistic association between nonbacterial prostatitis and levels of urate and creatinine in expressed prostatic secretion. J Urol  1996,155(3),958-960","journal-title":"J Urol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/bju.12118","volume":"112","author":"Gandaglia G.","year":"2013","unstructured":"Gandaglia G.; Briganti A.; Gontero P.; Mondaini N.; Novara G.; Salonia A.; Sciarra A.; Montorsi F.; The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (). BJU Int  2013,112(4),432-441","journal-title":"BJU Int"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"548497","DOI":"10.1155\/2013\/548497","author":"Kaur K.","year":"2013","unstructured":"Kaur K.; Prabha V.; Impairment by sperm agglutinating factor isolated from Escherichia coli: Receptor specific interactions. Biomed Res  Int 2013  2013,548497","journal-title":"Biomed Res  Int 2013"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ccr.2013.06.014","volume":"24","author":"Patra K.C.","year":"2013","unstructured":"Patra K.C.; Wang Q.; Bhaskar P.T.; Miller L.; Wang Z.; Wheaton W.; Chandel N.; Laakso M.; Muller W.J.; Allen E.L.; Jha A.K.; Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer Cancer Cell  2013,24(2),213-228","journal-title":"Cancer Cell"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"Vander Heiden M.G.","year":"2009","unstructured":"Vander Heiden M.G.; Cantley L.C.; Thompson C.B.; Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science  2009,324(5930),1029-1033","journal-title":"Science"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1126\/science.1174229","volume":"325","author":"Yun J.","year":"2009","unstructured":"Yun J.; Rago C.; Cheong I.; Pagliarini R.; Angenendt P.; Rajagopalan H.; Schmidt K.; Willson J.K.V.; Markowitz S.; Zhou S.; Diaz L.A.; Velculescu V.E.; Lengauer C.; Kinzler K.W.; Vogelstein B.; Papadopoulos N.; Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science  2009,325(5947),1555-1559","journal-title":"Science"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"689","DOI":"10.3892\/or_00000061","volume":"20","author":"Han Y.H.","year":"2008","unstructured":"Han Y.H.; Kim S.H.; Kim S.Z.; Park W.H.; Antimycin A as a mitochondrial electron transport inhibitor prevents the growth of human lung cancer A549 cells. Oncol Rep  2008,20(3),689-693","journal-title":"Oncol Rep"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.molcel.2014.09.026","volume":"56","author":"Schell J.C.","year":"2014","unstructured":"Schell J.C.; Olson K.A.; Jiang L.; Hawkins A.J.; Van Vranken J.G.; Xie J.; Egnatchik R.A.; Earl E.G.; DeBerardinis R.J.; Rutter J.; A role for the mitochondrial pyruvate carrier as a repressor of the Warburg effect and colon cancer cell growth. Mol Cell  2014,56(3),400-413","journal-title":"Mol Cell"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1126\/science.1218530","volume":"337","author":"Herzig S.","year":"2012","unstructured":"Herzig S.; Raemy E.; Montessuit S.; Veuthey J.L.; Zamboni N.; Westermann B.; Kunji E.R.S.; Martinou J.C.; Identification and functional expression of the mitochondrial pyruvate carrier. Science  2012,337(6090),93-96","journal-title":"Science"},{"key":"ref=51","first-page":"5068","volume":"43","author":"Paradies G.","year":"1983","unstructured":"Paradies G.; Capuano F.; Palombini G.; Galeotti T.; Papa S.; Transport of pyruvate in mitochondria from different tumor cells. Cancer Res  1983,43(11),5068-5071","journal-title":"Cancer Res"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1038\/emboj.2011.158","volume":"30","author":"Massie C.E.","year":"2011","unstructured":"Massie C.E.; Lynch A.; Ramos-Montoya A.; Boren J.; Stark R.; Fazli L.; Warren A.; Scott H.; Madhu B.; Sharma N.; Bon H.; Zecchini V.; Smith D.M.; DeNicola G.M.; Mathews N.; Osborne M.; Hadfield J.; MacArthur S.; Adryan B.; Lyons S.K.; Brindle K.M.; Griffiths J.; Gleave M.E.; Rennie P.S.; Neal D.E.; Mills I.G.; The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J  2011,30(13),2719-2733","journal-title":"EMBO J"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrurol.2013.43","volume":"10","author":"Kolenko V.","year":"2013","unstructured":"Kolenko V.; Teper E.; Kutikov A.; Uzzo R.; Zinc and zinc transporters in prostate carcinogenesis. Nat Rev Urol  2013,10(4),219-226","journal-title":"Nat Rev Urol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1517\/14656561003709748","volume":"11","author":"Murphy A.B.","year":"2010","unstructured":"Murphy A.B.; Nadler R.B.; Pharmacotherapy strategies in chronic prostatitis\/chronic pelvic pain syndrome management. Expert Opin Pharmacother  2010,11(8),1255-1261","journal-title":"Expert Opin Pharmacother"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/aja.2011.36","volume":"13","author":"Magri V.","year":"2011","unstructured":"Magri V.; Montanari E.; \u0160kerk V.; Markoti\u0107 A.; Marras E.; Restelli A.; Naber K.G.; Perletti G.; Fluoroquinolone\u2013macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction. Asian J Androl  2011,13(6),819-827","journal-title":"Asian J Androl"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jnutbio.2015.06.005","volume":"26","author":"Seo M.J.","year":"2015","unstructured":"Seo M.J.; Lee Y.J.; Hwang J.H.; Kim K.J.; Lee B.Y.; The inhibitory effects of quercetin on obesity and obesity-induced inflammation by regulation of MAPK signaling. J Nutr Biochem  2015,26(11),1308-1316","journal-title":"J Nutr Biochem"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.lfs.2015.07.015","volume":"137","author":"Liao Y.R.","year":"2015","unstructured":"Liao Y.R.; Lin J.Y.; Quercetin intraperitoneal administration ameliorates lipopolysaccharide-induced systemic inflammation in mice. Life Sci  2015,137,89-97","journal-title":"Life Sci"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/S0090-4295(99)00358-1","volume":"54","author":"Shoskes D.A.","year":"1999","unstructured":"Shoskes D.A.; Zeitlin S.I.; Shahed A.; Rajfer J.; Quercetin in men with category III chronic prostatitis: A preliminary prospective, double-blind, placebo-controlled trial. Urology  1999,54(6),960-963","journal-title":"Urology"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.eururo.2009.05.046","volume":"56","author":"Wagenlehner F.M.E.","year":"2009","unstructured":"Wagenlehner F.M.E.; Schneider H.; Ludwig M.; Schnitker J.; Br\u00e4hler E.; Weidner W.; A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: A multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. Eur Urol  2009,56(3),544-551","journal-title":"Eur Urol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1097\/01.ju.0000054983.45096.16","volume":"169","author":"Nickel J.C.","year":"2003","unstructured":"Nickel J.C.; Pontari M.; Moon T.; Gittelman M.; Malek G.; Farrington J.; Pearson J.; Krupa D.; Bach M.; Drisko J.; A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. J Urol  2003,169(4),1401-1405","journal-title":"J Urol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1590\/S0100-879X2009005000021","volume":"42","author":"Zhao W.P.","year":"2009","unstructured":"Zhao W.P.; Zhang Z.G.; Li X.D.; Yu D.; Rui X.F.; Li G.H.; Ding G.Q.; Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA). Braz J Med Biol Res  2009,42(10),963-967","journal-title":"Braz J Med Biol Res"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1464-410X.2007.06667.x","volume":"99","author":"Bates S.M.","year":"2007","unstructured":"Bates S.M.; Hill V.A.; Anderson J.B.; Chapple C.R.; Spence R.; Ryan C.; Talbot M.D.; A prospective, randomized, double-blind trial to evaluate the role of a short reducing course of oral corticosteroid therapy in the treatment of chronic prostatitis\/chronic pelvic pain syndrome. BJU Int  2007,99(2),355-359","journal-title":"BJU Int"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1001\/archinternmed.2010.319","volume":"170","author":"Pontari M.A.","year":"2010","unstructured":"Pontari M.A.; Krieger J.N.; Litwin M.S.; White P.C.; Anderson R.U.; McNaughton-Collins M.; Nickel J.C.; Shoskes D.A.; Alexander R.B.; O\u2019Leary M.; Zeitlin S.; Chuai S.; Landis J.R.; Cen L.; Propert K.J.; Kusek J.W.; Nyberg L.M.; Schaeffer A.J.; Pregabalin for the treatment of men with chronic prostatitis\/chronic pelvic pain syndrome: A randomized controlled trial. Arch Intern Med  2010,170(17),1586-1593","journal-title":"Arch Intern Med"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00508-005-0464-2","volume":"117","author":"Sator-Katzenschlager S.M.","year":"2005","unstructured":"Sator-Katzenschlager S.M.; Scharbert G.; Kress H.G.; Frickey N.; Ellend A.; Gleiss A.; Kozek-Langenecker S.A.; Chronic pelvic pain treated with gabapentin and amitriptyline: A randomized controlled pilot study. Wien Klin Wochenschr  2005,117(21-22),761-768","journal-title":"Wien Klin Wochenschr"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/S0022-5347(11)60282-6","volume":"185","author":"Berger R.E.","year":"2011","unstructured":"Berger R.E.; Re: Pregabalin for the treatment of men with chronic prostatitis\/chronic pelvic pain syndrome: A randomized controlled trial. J Urol  2011,185(4),1302-1303","journal-title":"J Urol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"134","DOI":"10.4103\/0253-7613.178825","volume":"48","author":"Manjunatha R.","year":"2016","unstructured":"Manjunatha R.; Pundarikaksha H.P.; Madhusudhana H.R.; Amarkumar J.; Hanumantharaju B.K.; A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia. Indian J Pharmacol  2016,48(2),134-140","journal-title":"Indian J Pharmacol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1111\/j.1742-1241.2011.02731.x","volume":"65","author":"Mirone V.","year":"2011","unstructured":"Mirone V.; Sessa A.; Giuliano F.; Berges R.; Kirby M.; Moncada I.; Current benign prostatic hyperplasia treatment: Impact on sexual function and management of related sexual adverse events. Int J Clin Pract  2011,65(9),1005-1013","journal-title":"Int J Clin Pract"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1756287221993283","DOI":"10.1177\/1756287221993283","volume":"13","author":"Mari A.","year":"2021","unstructured":"Mari A.; Antonelli A.; Cindolo L.; Fusco F.; Minervini A.; De Nunzio C.; Alfuzosin for the medical treatment of benign prostatic hyperplasia and lower urinary tract symptoms: A systematic review of the literature and narrative synthesis. Ther Adv Urol  2021,13,1756287221993283","journal-title":"Ther Adv Urol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00345-010-0537-3","volume":"29","author":"Chen Y.","year":"2011","unstructured":"Chen Y.; Wu X.; Liu J.; Tang W.; Zhao T.; Zhang J.; Effects of a 6-month course of tamsulosin for chronic prostatitis\/chronic pelvic pain syndrome: A multicenter, randomized trial. World J Urol  2011,29(3),381-385","journal-title":"World J Urol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2147\/dddt.s10428","volume":"4","author":"Rossi M.","year":"2010","unstructured":"Rossi M.; Roumegu\u00e8re T.; Silodosin in the treatment of benign prostatic hyperplasia. Drug Des Devel Ther  2010,4,291-297","journal-title":"Drug Des Devel Ther"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0022-5347(05)00032-7","volume":"175","author":"McVary K.T.","year":"2006","unstructured":"McVary K.T.; Alfuzosin for symptomatic benign prostatic hyperplasia: Long-term experience. J Urol  2006,175(1),35-42","journal-title":"J Urol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11934-020-01009-7","volume":"21","author":"Sebastianelli A.","year":"2020","unstructured":"Sebastianelli A.; Spatafora P.; Morselli S.; Vignozzi L.; Serni S.; McVary K.T.; Kaplan S.; Gravas S.; Chapple C.; Gacci M.; Tadalafil alone or in combination with tamsulosin for the management for LUTS\/BPH and ED. Curr Urol Rep  2020,21(12),56","journal-title":"Curr Urol Rep"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0303-7207(02)00368-4","volume":"198","author":"Imperato-McGinley J.","year":"2002","unstructured":"Imperato-McGinley J.; Zhu Y. S.; Androgens and male physiology the syndrome of 5\u03b1-reductase-2 deficiency. Mol Cell Endocrinol  2002,198(1-2),51-59","journal-title":"Mol Cell Endocrinol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJM197410312911806","volume":"291","author":"Walsh P.C.","year":"1974","unstructured":"Walsh P.C.; Madden J.D.; Harrod M.J.; Goldstein J.L.; MacDonald P.C.; Wilson J.D.; Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med  1974,291(18),944-949","journal-title":"N Engl J Med"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3727\/000000001783992551","volume":"9","author":"Dadras S. S.","year":"2001","unstructured":"Dadras S. S.; Cai X.; Abasolo I.; Wang Z.; Inhibition of 5\u03b1-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone. Gene Expr  2001,9(4-5),183-194","journal-title":"Gene Expr"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jsbmb.2006.09.032","volume":"102","author":"Raynaud J.P.","year":"2006","unstructured":"Raynaud J.P.; Prostate cancer risk in testosterone-treated men. J Steroid Biochem Mol Biol  2006,102(1-5),261-266","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.1210\/endo.140.10.7039","volume":"140","author":"Wright A.S.","year":"1999","unstructured":"Wright A.S.; Douglas R.C.; Thomas L.N.; Lazier C.B.; Rittmaster R.S.; Androgen-induced regrowth in the castrated rat ventral prostate: Role of 5\u03b1-reductase. Endocrinology  1999,140(10),4509-4515","journal-title":"Endocrinology"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/oxfordjournals.jncimonographs.a024244","volume":"2000","author":"Bosland M.C.","year":"2000","unstructured":"Bosland M.C.; The role of steroid hormones in prostate carcinogenesis. JNCI Monographs  2000,2000(27),39-66","journal-title":"JNCI Monographs"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.3109\/14756366.2012.729827","volume":"28","author":"Bratoeff E.","year":"2013","unstructured":"Bratoeff E.; S\u00e1nchez A.; Arellano Y.; Heuze Y.; Soriano J.; Cabeza M.; In vivo and in vitro effect of androstene derivatives as 5\u03b1-reductase type 1 enzyme inhibitors. J Enzyme Inhib Med Chem  2013,28(6),1247-1254","journal-title":"J Enzyme Inhib Med Chem"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.1038\/s41467-020-19249-z","volume":"11","author":"Xiao Q.","year":"2020","unstructured":"Xiao Q.; Wang L.; Supekar S.; Shen T.; Liu H.; Ye F.; Huang J.; Fan H.; Wei Z.; Zhang C.; Structure of human steroid 5\u03b1-reductase 2 with the anti-androgen drug finasteride. Nat Commun  2020,11(1),5430","journal-title":"Nat Commun"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/pros.22694","volume":"73","author":"Wu Y.","year":"2013","unstructured":"Wu Y.; Godoy A.; Azzouni F.; Wilton J.H.; Ip C.; Mohler J.L.; Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5\u03b1-reductase inhibitors. Prostate  2013,73(13),1470-1482","journal-title":"Prostate"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev.bi.63.070194.000325","volume":"63","author":"Russell D.W.","year":"1994","unstructured":"Russell D.W.; Wilson J.D.; Steroid 5\u03b1-reductase: Two genes\/two enzymes. Annu Rev Biochem  1994,63(1),25-61","journal-title":"Annu Rev Biochem"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1349-7006.2007.00656.x","volume":"99","author":"Uemura M.","year":"2008","unstructured":"Uemura M.; Tamura K.; Chung S.; Honma S.; Okuyama A.; Nakamura Y.; Nakagawa H.; Novel 5\u03b1-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci  2008,99(1),81-86","journal-title":"Cancer Sci"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"19548","DOI":"10.1016\/S0021-9258(18)41809-1","volume":"267","author":"Normington K.","year":"1992","unstructured":"Normington K.; Russell D.W.; Tissue distribution and kinetic characteristics of rat steroid 5 \u03b1-reductase isozymes. Evidence for distinct physiological functions. J Biol Chem  1992,267(27),19548-19554","journal-title":"J Biol Chem"},{"key":"ref=85","author":"McEwan I.J.","unstructured":"McEwan I.J.; Brinkmann A.O.; Androgen physiology: Receptor and metabolic disorders. Endotext   MDText.com, Inc. 2000.","journal-title":"Endotext"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"25395","DOI":"10.18632\/aging.104142","volume":"12","author":"Mai Q.","year":"2020","unstructured":"Mai Q.; Sheng D.; Chen C.; Gou Q.; Chen M.; Huang X.; Yin H.; Chen X.; Chen Z.; Steroid 5 \u03b1-reductase 3 (SRD5A3) promotes tumor growth and predicts poor survival of human hepatocellular carcinoma (HCC). Aging  2020,12(24),25395-25411","journal-title":"Aging"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cell.2010.06.001","volume":"142","author":"Cantagrel V.","year":"2010","unstructured":"Cantagrel V.; Lefeber D.J.; Ng B.G.; Guan Z.; Silhavy J.L.; Bielas S.L.; Lehle L.; Hombauer H.; Adamowicz M.; Swiezewska E.; De Brouwer A.P.; Bl\u00fcmel P.; Sykut-Cegielska J.; Houliston S.; Swistun D.; Ali B.R.; Dobyns W.B.; Babovic-Vuksanovic D.; van Bokhoven H.; Wevers R.A.; Raetz C.R.H.; Freeze H.H.; Morava \u00c9.; Al-Gazali L.; Gleeson J.G.; SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder. Cell  2010,142(2),203-217","journal-title":"Cell"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","volume":"68","author":"Montgomery R.B.","year":"2008","unstructured":"Montgomery R.B.; Mostaghel E.A.; Vessella R.; Hess D.L.; Kalhorn T.F.; Higano C.S.; True L.D.; Nelson P.S.; Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res  2008,68(11),4447-4454","journal-title":"Cancer Res"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1172\/JCI116665","volume":"92","author":"Thigpen A.E.","year":"1993","unstructured":"Thigpen A.E.; Silver R.I.; Guileyardo J.M.; Casey M.L.; McConnell J.D.; Russell D.W.; Tissue distribution and ontogeny of steroid 5 \u03b1-reductase isozyme expression. J Clin Invest  1993,92(2),903-910","journal-title":"J Clin Invest"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1159\/000496289","volume":"65","author":"Madersbacher S.","year":"2019","unstructured":"Madersbacher S.; Sampson N.; Culig Z.; Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: A mini-review. Gerontology  2019,65(5),458-464","journal-title":"Gerontology"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/S0006-291X(87)80490-4","volume":"144","author":"Chan W.K.","year":"1987","unstructured":"Chan W.K.; Fong C.Y.; Tiong H.H.; Tan C.H.; The ihibition of 3\u03b2HSD activity in porcine granulosa cells by 4- MA, a potent 5\u03b1-reductase inhibitor. Biochem Biophys Res Commun  1987,144(1),166-171","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/j.1939-4640.1991.tb00272.x","volume":"12","author":"McConnell J.D.","year":"1991","unstructured":"McConnell J.D.; The pathophysiology of benign prostatic hyperplasia. J Androl  1991,12(6),356-363","journal-title":"J Androl"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/0960-0760(94)90151-1","volume":"48","author":"Di Salle E.","year":"1994","unstructured":"Di Salle E.; Briatico G.; Giudici D.; Ornati G.; Panzeri A.; Endocrine properties of the testosterone 5\u03b1-reductase inhibitor turosteride (FCE 26073). J Steroid Biochem Mol Biol  1994,48(2-3),241-248","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.febslet.2007.11.016","volume":"582","author":"Sonoda J.","year":"2008","unstructured":"Sonoda J.; Pei L.; Evans R.M.; Nuclear receptors: Decoding metabolic disease. FEBS Lett  2008,582(1),2-9","journal-title":"FEBS Lett"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2165\/00003495-199957040-00008","volume":"57","author":"Wilde M.I.","year":"1999","unstructured":"Wilde M.I.; Goa K.L.; Finasteride. Drugs  1999,57(4),557-581","journal-title":"Drugs"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1021\/bi00072a028","volume":"32","author":"Faller B.","year":"1993","unstructured":"Faller B.; Farley D.; Nick H.; Finasteride: A slow-binding 5\u03b1-reductase inhibitor. Biochemistry  1993,32(21),5705-5710","journal-title":"Biochemistry"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0006-2952(01)00728-6","volume":"62","author":"Darren Stuart J.","year":"2001","unstructured":"Darren Stuart J.; Lee F.W.; Simpson Noel D.; Kadwell S.H.; Overton L.K.; Hoffman C.R.; Kost T.A.; Tippin T.K.; Yeager R.L.; Batchelor K.W.; Neal Bramson H.; Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5\u03b1-reductases: Determinants for different in vivo activities of GI198745 and finasteride in the rat. Biochem Pharmacol  2001,62(7),933-942","journal-title":"Biochem Pharmacol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"905","DOI":"10.2165\/00002512-200320120-00005","volume":"20","author":"Evans H.C.","year":"2003","unstructured":"Evans H.C.; Goa K.L.; Dutasteride. Drugs Aging  2003,20(12),905-916","journal-title":"Drugs Aging"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1210\/jc.2003-030330","volume":"89","author":"Clark R.V.","year":"2004","unstructured":"Clark R.V.; Hermann D.J.; Cunningham G.R.; Wilson T.H.; Morrill B.B.; Hobbs S.; Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5\u03b1-reductase inhibitor. J Clin Endocrinol Metab  2004,89(5),2179-2184","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1464-410X.2005.05909.x","volume":"97","author":"Schulman C.","year":"2006","unstructured":"Schulman C.; Pommerville P.; H\u00f6fner K.; Wachs B.; Long-term therapy with the dual 5\u03b1-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia. BJU Int  2006,97(1),73-80","journal-title":"BJU Int"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0302-2838(03)00198-2","volume":"44","author":"Andriole G.L.","year":"2003","unstructured":"Andriole G.L.; Kirby R.; Safety and tolerability of the dual 5\u03b1-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol  2003,44(1),82-88","journal-title":"Eur Urol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/pros.10340","volume":"58","author":"Lazier C. B.","year":"2004","unstructured":"Lazier C. B.; Thomas L. N.; Douglas R. C.; Vessey J. P.; Rittmaster R. S.; Dutasteride, the dual 5\u03b1-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate  2004,58(2),130-144","journal-title":"Prostate"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1021\/jm00014a015","volume":"38","author":"Frye S. V.","year":"1995","unstructured":"Frye S. V.; Haffner C. D.; Maloney P. R.; Hiner R. N.; Dorsey G. F.; Noe R. A.; Unwalla R. J.; Batchelor K. W.; Bramson H. N.; Stuart J. D.; Structure-activity relationships for inhibition of type 1 and 2 human 5\u03b1-reductase and human adrenal 3\u03b2-hydroxy-\u0394-steroid dehydrogenase\/3-keto-\u0394-steroid isomerase by 6-azaandrost-4-en-3-ones: Optimization of the C-17 substituent. J Med Chem  1995,38(14),2621-2627","journal-title":"J Med Chem"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.steroids.2004.11.008","volume":"70","author":"P\u00e9rez-ornelas V.","year":"2005","unstructured":"P\u00e9rez-ornelas V.; Cabeza M.; Bratoeff E.; Heuze I.; S\u00e1nchez M.; Ram\u00edrez E.; Naranjorodr\u00edguez E.; New 5\u03b1-reductase inhibitors: In vitro and in vivo effects. Steroids  2005,70(3),217-224","journal-title":"Steroids"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jsbmb.2008.06.014","volume":"111","author":"Bratoeff E.","year":"2008","unstructured":"Bratoeff E.; Cabeza M.; P\u00e9rez-Ornelas V.; Recillas S.; Heuze I.; In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5\u03b1-reductase inhibitors. J Steroid Biochem Mol Biol  2008,111(3-5),275-281","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.steroids.2008.03.006","volume":"73","author":"Cabeza M.","year":"2008","unstructured":"Cabeza M.; Bratoeff E.; Ram\u00edrez E.; Heuze I.; Recillas S.; Berrios H.; Cruz A.; Cabrera O.; P\u00e9rez V.; Biological activity of novel progesterone derivatives having a bulky ester side chains at C-3. Steroids  2008,73(8),838-843","journal-title":"Steroids"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jsbmb.2008.06.011","volume":"111","author":"Cabeza M.","year":"2008","unstructured":"Cabeza M.; Bratoeff E.; G\u00f3mez G.; Heuze I.; Rojas A.; Ochoa M.; Palomino M.A.; Revilla C.; Synthesis and biological effect of halogen substituted phenyl acetic acid derivatives of progesterone as potent progesterone receptor antagonists. J Steroid Biochem Mol Biol  2008,111(3-5),232-239","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jsbmb.2007.03.038","volume":"107","author":"Bratoeff E.","year":"2007","unstructured":"Bratoeff E.; Sainz T.; Cabeza M.; Heuze I.; Recillas S.; P\u00e9rez V.; Rodr\u00edguez C.; Segura T.; Gonz\u00e1les J.; Ram\u00edrez E.; Steroids with a carbamate function at C-17, a novel class of inhibitors for human and hamster steroid 5\u03b1-reductase. J Steroid Biochem Mol Biol  2007,107(1-2),48-56","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.steroids.2011.05.015","volume":"76","author":"Arellano Y.","year":"2011","unstructured":"Arellano Y.; Bratoeff E.; Garrido M.; Soriano J.; Heuze Y.; Cabeza M.; New ester derivatives of dehydroepiandrosterone as 5\u03b1-reductase inhibitors. Steroids  2011,76(12),1241-1246","journal-title":"Steroids"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jsbmb.2011.07.001","volume":"127","author":"Garrido M.","year":"2011","unstructured":"Garrido M.; Bratoeff E.; Bonilla D.; Soriano J.; Heuze Y.; Cabeza M.; New steroidal lactones as 5\u03b1-reductase inhibitors and antagonists for the androgen receptor. J Steroid Biochem Mol Biol  2011,127(3-5),367-373","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=111","first-page":"143","volume":"45","author":"Di Silverio F.","year":"1993","unstructured":"Di Silverio F.; Flammia G.P.; Sciarra A.; Caponera M.; Mauro M.; Buscarini M.; Tavani M.; D\u2019Eramo G.; Plant extracts in BPH. Minerva Urol Nefrol  1993,45(4),143-149","journal-title":"Minerva Urol Nefrol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1046\/j.1464-410X.1996.00104.x","volume":"78","author":"Buck A. C.","year":"1996","unstructured":"Buck A. C.; Phytotherapy for the prostate. Brit J Urol  1996,78(3),325-336","journal-title":"Brit J Urol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/S0002-9343(00)00604-5","volume":"109","author":"Ishani A.","year":"2000","unstructured":"Ishani A.; MacDonald R.; Nelson D.; Rutks I.; Wilt T.J.; Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: A systematic review and quantitative meta-analysis. Am J Med  2000,109(8),654-664","journal-title":"Am J Med"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0090-4295(99)00028-X","volume":"54","author":"Bales G.T.","year":"1999","unstructured":"Bales G.T.; Christiano A.P.; Kirsh E.J.; Gerber G.S.; Phytotherapeutic agents in the treatment of lower urinary tract symptoms: A demographic analysis of awareness and use at the University of Chicago. Urology  1999,54(1),86-89","journal-title":"Urology"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/(SICI)1097-0045(199610)29:4<231::AID-PROS4>3.0.CO;2-E","volume":"29","author":"Carraro J.C.","year":"1996","unstructured":"Carraro J.C.; Raynaud J.P.; Koch G.; Chisholm G.D.; Di Silverio F.; Teillac P.; Da Silva F.C.; Cauquil J.; Chopin D.K.; Hamdy F.C.; Hanus M.; Hauri D.; Kalinteris A.; Marencak J.; Perier A.; Perrin P.; Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients. Prostate  1996,29(4),231-240","journal-title":"Prostate"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1001\/jama.280.18.1604","volume":"280","author":"Wilt T.J.","year":"1998","unstructured":"Wilt T.J.; Ishani A.; Stark G.; MacDonald R.; Lau J.; Mulrow C.; Saw palmetto extracts for treatment of benign prostatic hyperplasia: A systematic review. JAMA  1998,280(18),1604-1609","journal-title":"JAMA"},{"key":"ref=117","first-page":"239","volume":"120","author":"Morzycki J.W.","year":"1985","unstructured":"Morzycki J.W.; Sicinski R.R.; Synthesis of 6,7-diazacholestane derivatives. Acta Chir Hung  1985,120(4),239-246","journal-title":"Acta Chir Hung"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1017\/S1368980000000549","volume":"3","author":"Wilt T.J.","year":"2000","unstructured":"Wilt T.J.; Ishani A.; Rutks I.; MacDonald R.; Phytotherapy for benign prostatic hyperplasia. Public Health Nutr  2000,3(4a),459-472","journal-title":"Public Health Nutr"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S0090-4295(00)01052-9","volume":"57","author":"Marks L.S.","year":"2001","unstructured":"Marks L.S.; Hess D.L.; Dorey F.J.; Luz Macairan M.; Cruz Santos P.B.; Tyler V.E.; Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. Urology  2001,57(5),999-1005","journal-title":"Urology"},{"key":"ref=120","first-page":"153","volume":"46","author":"Cabeza M.","year":"2003","unstructured":"Cabeza M.; Bratoeff E.; Heuze I.; Ram\u00edrez E.; S\u00e1nchez M.; Flores E.; Effect of beta-sitosterol as inhibitor of 5 \u03b1-reductase in hamster prostate. Proc West Pharmacol Soc  2003,46,153-155","journal-title":"Proc West Pharmacol Soc"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000472613","volume":"12","author":"Kadow C.","year":"1986","unstructured":"Kadow C.; Abrams P.H.; A double-blind trial of the effect of \u03b2-sitosteryl glucoside (WA184) in the treatment of benign prostatic hyperplasia. Eur Urol  1986,12(3),187-189","journal-title":"Eur Urol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/S0140-6736(95)91085-9","volume":"345","author":"Berges R.R.","year":"1995","unstructured":"Berges R.R.; Windeler J.; Trampisch H.J.; Senge T.; \u03b2-sitosterol study, Randomized, placebo-controlled, double-blind clinical trial of \u03b2-sitosterol in patients with benign prostatic hyperplasia. Lancet  1995,345(8964),1529-1532","journal-title":"Lancet"},{"key":"ref=123","first-page":"219","volume":"75","author":"Cambronero J.","year":"2022","unstructured":"Cambronero J.; Osca-Garc\u00eda J.M.; Merino-Salas S.; Miguel J.M.; Borralleras C.; L\u00f3pez-Alcina E.; Effectiveness of treatment with Pygeum africanum in patients with lower urinary tract symptoms and benign prostatic hyperplasia: A cross-sectional study in the real-world clinical practice in Spain (The PROFIT Study). Arch Esp Urol  2022,75(3),219-227","journal-title":"Arch Esp Urol"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1055\/s-2006-946638","volume":"72","author":"Schleich S.","year":"2006","unstructured":"Schleich S.; Papaioannou M.; Baniahmad A.; Matusch R.; Extracts from Pygeum africanum and other ethnobotanical species with antiandrogenic activity. Planta Med  2006,72(9),807-813","journal-title":"Planta Med"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s12020-007-0014-y","volume":"31","author":"Shenouda N.S.","year":"2007","unstructured":"Shenouda N.S.; Sakla M.S.; Newton L.G.; Besch-Williford C.; Greenberg N.M.; MacDonald R.S.; Lubahn D.B.; Phytosterol Pygeum africanum regulates prostate cancer in vitro and in vivo. Endocr J  2007,31(1),72-81","journal-title":"Endocr J"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1007\/s11596-015-1499-x","volume":"35","author":"Wang T.","year":"2015","unstructured":"Wang T.; Xie Z.; Huang Z.; Li H.; Wei A.; Di J.; Xiao H.; Zhang Z.; Cai L.; Tao X.; Qi T.; Chen D.; Chen J.; Total triterpenoids from Ganoderma lucidum suppresses prostate cancer cell growth by inducing growth arrest and apoptosis. J Huazhong Univ Sci Technolog Med Sci  2015,35(5),736-741","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jep.2005.05.041","volume":"102","author":"Fujita R.","year":"2005","unstructured":"Fujita R.; Liu J.; Shimizu K.; Konishi F.; Noda K.; Kumamoto S.; Ueda C.; Tajiri H.; Kaneko S.; Suimi Y.; Kondo R.; Anti-androgenic activities of Ganoderma lucidum. J Ethnopharmacol  2005,102(1),107-112","journal-title":"J Ethnopharmacol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"4966","DOI":"10.1016\/j.bmc.2007.04.036","volume":"15","author":"Liu J.","year":"2007","unstructured":"Liu J.; Shimizu K.; Konishi F.; Kumamoto S.; Kondo R.; The anti-androgen effect of ganoderol B isolated from the fruiting body of Ganoderma lucidum. Bioorg Med Chem  2007,15(14),4966-4972","journal-title":"Bioorg Med Chem"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"e0199738","DOI":"10.1371\/journal.pone.0199738","volume":"13","author":"Loyd A.L.","year":"2018","unstructured":"Loyd A.L.; Barnes C.W.; Held B.W.; Schink M.J.; Smith M.E.; Smith J.A.; Blanchette R.A.; Elucidating \u201clucidum\u201d: Distinguishing the diverse laccate Ganoderma species of the United States. PLoS One  2018,13(7),e0199738","journal-title":"PLoS One"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1158\/0008-5472.CAN-10-2581","volume":"71","author":"Frigo D.E.","year":"2011","unstructured":"Frigo D.E.; Howe M.K.; Wittmann B.M.; Brunner A.M.; Cushman I.; Wang Q.; Brown M.; Means A.R.; McDonnell D.P.; CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells. Cancer Res  2011,71(2),528-537","journal-title":"Cancer Res"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3389\/fonc.2017.00131","volume":"7","author":"Eidelman E.","year":"2017","unstructured":"Eidelman E.; Twum-Ampofo J.; Ansari J.; Siddiqui M.M.; The metabolic phenotype of prostate cancer. Front Oncol  2017,7,131","journal-title":"Front Oncol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.urology.2006.04.016","volume":"68","author":"Ryan C.J.","year":"2006","unstructured":"Ryan C.J.; Smith A.; Lal P.; Satagopan J.; Reuter V.; Scardino P.; Gerald W.; Scher H.I.; Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: An early predictor of relapse or incomplete androgen suppression. Urology  2006,68(4),834-839","journal-title":"Urology"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1097\/01.LAB.0000038924.67707.75","volume":"82","author":"Hyytinen E.R.","year":"2002","unstructured":"Hyytinen E.R.; Haapala K.; Thompson J.; Lappalainen I.; Roiha M.; Rantala I.; Helin H.J.; J\u00e4nne O.A.; Vihinen M.; Palvimo J.J.; Koivisto P.A.; Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer. Lab Invest  2002,82(11),1591-1598","journal-title":"Lab Invest"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/B978-0-12-802388-4.00004-5","author":"Buskiewicz I.A.","year":"2016","unstructured":"Buskiewicz I.A.; Huber S.A.; Fairweather D.; Sex hormone receptor expression in the immune system. Sex Differences in Physiology  2016,45-60","journal-title":"Sex Differences in Physiology"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"6098","DOI":"10.4049\/jimmunol.173.10.6098","volume":"173","author":"Roden A.C.","year":"2004","unstructured":"Roden A.C.; Moser M.T.; Tri S.D.; Mercader M.; Kuntz S.M.; Dong H.; Hurwitz A.A.; McKean D.J.; Celis E.; Leibovich B.C.; Allison J.P.; Kwon E.D.; Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol  2004,173(10),6098-6108","journal-title":"J Immunol"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"9887","DOI":"10.1073\/pnas.1402468111","volume":"111","author":"Kissick H.T.","year":"2014","unstructured":"Kissick H.T.; Sanda M.G.; Dunn L.K.; Pellegrini K.L.; On S.T.; Noel J.K.; Arredouani M.S.; Androgens alter T- cell immunity by inhibiting T-helper 1 differentiation. Proc Natl Acad Sci  2014,111(27),9887-9892","journal-title":"Proc Natl Acad Sci"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ccr.2005.01.027","volume":"7","author":"Drake C.G.","year":"2005","unstructured":"Drake C.G.; Doody A.D.H.; Mihalyo M.A.; Huang C.T.; Kelleher E.; Ravi S.; Hipkiss E.L.; Flies D.B.; Kennedy E.P.; Long M.; McGary P.W.; Coryell L.; Nelson W.G.; Pardoll D.M.; Adler A.J.; Androgen ablation mitigates tolerance to a prostate\/prostate cancer-restricted antigen. Cancer Cell  2005,7(3),239-249","journal-title":"Cancer Cell"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1172\/JCI200113183","volume":"108","author":"Olsen N.J.","year":"2001","unstructured":"Olsen N.J.; Gu X.; Kovacs W.J.; Bone marrow stromal cells mediate androgenic suppression of B lymphocyte development. J Clin Invest  2001,108(11),1697-1704","journal-title":"J Clin Invest"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"14565","DOI":"10.1073\/pnas.251140998","volume":"98","author":"Mercader M.","year":"2001","unstructured":"Mercader M.; Bodner B.K.; Moser M.T.; Kwon P.S.; Park E.S.Y.; Manecke R.G.; Ellis T.M.; Wojcik E.M.; Yang D.; Flanigan R.C.; Waters W.B.; Kast W.M.; Kwon E.D.; T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci  2001,98(25),14565-14570","journal-title":"Proc Natl Acad Sci"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1016\/j.ajpath.2014.06.022","volume":"184","author":"Singh M.","year":"2014","unstructured":"Singh M.; Jha R.; Melamed J.; Shapiro E.; Hayward S.W.; Lee P.; Stromal androgen receptor in prostate development and cancer. Am J Pathol  2014,184(10),2598-2607","journal-title":"Am J Pathol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/0960-0760(93)90002-e","volume":"45","author":"Lin M.C.","year":"1993","unstructured":"Lin M.C.; Rajfer J.; Swerdloff R.S.; Gonz\u00e1lez-Cadavid N.F.; Testosterone down-regulates the levels of androgen receptor mRNA in smooth muscle cells from the rat corpora cavernosa via aromatization to estrogens. J Steroid Biochem Mol Biol  1993,45(5),333-43","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.humpath.2019.04.009","volume":"89","author":"Sehgal P.D.","year":"2019","unstructured":"Sehgal P.D.; Bauman T.M.; Nicholson T.M.; Vellky J.E.; Ricke E.A.; Tang W.; Xu W.; Huang W.; Ricke W.A.; Tissue-specific quantification and localization of androgen and estrogen receptors in prostate cancer. Hum Pathol  2019,89,99-108","journal-title":"Hum Pathol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/medsci8030028","volume":"8","author":"Barsouk A.","year":"2020","unstructured":"Barsouk A.; Padala S.A.; Vakiti A.; Mohammed A.; Saginala K.; Thandra K.C.; Rawla P.; Barsouk A.; Epidemiology, staging and management of prostate cancer. Med Sci  2020,8(3),28","journal-title":"Med Sci"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"r019","DOI":"10.1007\/s004240000075","volume":"439","author":"Vrecl M.","year":"2000","unstructured":"Vrecl M.; Heding A.; Hanyaloglu A.; Taylor P.L.; Eidne K.A.; Internalization kinetics of the gonadotropin-releasing hormone (GnRH) receptor. Pflugers Arch  2000,439(S1),r019-r020","journal-title":"Pflugers Arch"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1002\/cam4.4650","volume":"11","author":"Branigan G.L.","year":"2022","unstructured":"Branigan G.L.; Torrandell-Haro G.; Soto M.; Gelmann E.P.; Vitali F.; Rodgers K.E.; Brinton R.D.; Androgen-\ntargeting therapeutics mitigate the adverse effect of  agonist on the risk of neurodegenerative disease in men treated for prostate cancer. Cancer Med  2022,11(13),2687-2698","journal-title":"Cancer Med"},{"key":"ref=146","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases.  2012."},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"de Bono J.S.","year":"2011","unstructured":"de Bono J.S.; Logothetis C.J.; Molina A.; Fizazi K.; North S.; Chu L.; Chi K.N.; Jones R.J.; Goodman O.B.; Saad F.; Staffurth J.N.; Mainwaring P.; Harland S.; Flaig T.W.; Hutson T.E.; Cheng T.; Patterson H.; Hainsworth J.D.; Ryan C.J.; Sternberg C.N.; Ellard S.L.; Fl\u00e9chon A.; Saleh M.; Scholz M.; Efstathiou E.; Zivi A.; Bianchini D.; Loriot Y.; Chieffo N.; Kheoh T.; Haqq C.M.; Scher H.I.; Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med  2011,364(21),1995-2005","journal-title":"N Engl J Med"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.eururo.2018.03.028","volume":"75","author":"Nuhn P.","year":"2019","unstructured":"Nuhn P.; De Bono J.S.; Fizazi K.; Freedland S.J.; Grilli M.; Kantoff P.W.; Sonpavde G.; Sternberg C.N.; Yegnasubramanian S.; Antonarakis E.S.; Update on systemic prostate cancer therapies: Management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol  2019,75(1),88-99","journal-title":"Eur Urol"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"84572","DOI":"10.18632\/oncotarget.20028","volume":"8","author":"Moreira R.B.","year":"2017","unstructured":"Moreira R.B.; Debiasi M.; Francini E.; Nuzzo P.V.; Velasco G.D.; Maluf F.C.; Fay A.P.; Bellmunt J.; Choueiri T.K.; Schutz F.A.; Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: A meta-analysis of randomized controlled trials. Oncotarget  2017,8(48),84572-84578","journal-title":"Oncotarget"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3109\/00498254.2012.721022","volume":"43","author":"Acharya M.","year":"2013","unstructured":"Acharya M.; Gonz\u00e1lez M.; Mannens G.; De Vries R.; L\u00f3pez C.; Griffin T.; Tran N.; A phase I, open-label, single-dose, mass balance study of C-labeled abiraterone acetate in healthy male subjects. Xenobiotica  2013,43(4),379-389","journal-title":"Xenobiotica"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jamaoncol.2020.6973","volume":"7","author":"Wang L.","year":"2021","unstructured":"Wang L.; Paller C.J.; Hong H.; De Felice A.; Alexander G.C.; Brawley O.; Comparison of systemic treatments for metastatic castration-sensitive prostate cancer: A systematic review and network meta-analysis. JAMA Oncol  2021,7(3),412-420","journal-title":"JAMA Oncol"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673279207231228070533","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/225753\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673279207231228070533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T16:17:45Z","timestamp":1724948265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/225753\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":151,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0109298673279207231228070533","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-08-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}